{"title":"探索脑肿瘤靶向药物递送的治疗进展和策略。","authors":"Bjorn John Stephen, Madan Mohan Sharma, Devendra Jain, Harshdeep Dhaliwal, Vikram Sharma, Abhijeet Singh","doi":"10.1615/CritRevTherDrugCarrierSyst.2020033839","DOIUrl":null,"url":null,"abstract":"<p><p>Brain tumors pose a serious burden to health care because the cancers are usually incurable, despite advancements in treatment strategies including surgery, radiotherapy, and chemotherapy. Most studies report that specific drugs are effective in vitro, but many lose their therapeutic value in clinical settings. Maintaining therapeutic drug concentrations as an agent reaches a cancer target is the efficacy prerequisite for any form of treatment. However, in the case of brain tumors, the blood-brain barrier (BBB) acts to physically and physiologically block the drug, which complicates treatment options. In addition, strategies are limited by a number of factors such as difficulties that are associated with targeting tumor cells. The therapeutic potential of targeted drug delivery as an alternative to current strategies is gaining significant ground, with many studies highlighting its efficacy and compatibility in overcoming the BBB before reaching its final target in brain. In this review, we briefly describe basic physiology associated with the BBB and how modern science is taking advantage of physiological processes to deliver anticancer agents to brain. We also summarize different modes of drug delivery and highlight how nanoparticles as drug-delivery vehicles are used for drug transport in brain tumors as well as different types of surface modification that are used to increase target potential.</p>","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"38 2","pages":"1-25"},"PeriodicalIF":3.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploring Therapeutic Advancement and Strategies Associated with Drug Delivery in Brain-Tumor Targeting.\",\"authors\":\"Bjorn John Stephen, Madan Mohan Sharma, Devendra Jain, Harshdeep Dhaliwal, Vikram Sharma, Abhijeet Singh\",\"doi\":\"10.1615/CritRevTherDrugCarrierSyst.2020033839\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Brain tumors pose a serious burden to health care because the cancers are usually incurable, despite advancements in treatment strategies including surgery, radiotherapy, and chemotherapy. Most studies report that specific drugs are effective in vitro, but many lose their therapeutic value in clinical settings. Maintaining therapeutic drug concentrations as an agent reaches a cancer target is the efficacy prerequisite for any form of treatment. However, in the case of brain tumors, the blood-brain barrier (BBB) acts to physically and physiologically block the drug, which complicates treatment options. In addition, strategies are limited by a number of factors such as difficulties that are associated with targeting tumor cells. The therapeutic potential of targeted drug delivery as an alternative to current strategies is gaining significant ground, with many studies highlighting its efficacy and compatibility in overcoming the BBB before reaching its final target in brain. In this review, we briefly describe basic physiology associated with the BBB and how modern science is taking advantage of physiological processes to deliver anticancer agents to brain. We also summarize different modes of drug delivery and highlight how nanoparticles as drug-delivery vehicles are used for drug transport in brain tumors as well as different types of surface modification that are used to increase target potential.</p>\",\"PeriodicalId\":50614,\"journal\":{\"name\":\"Critical Reviews in Therapeutic Drug Carrier Systems\",\"volume\":\"38 2\",\"pages\":\"1-25\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical Reviews in Therapeutic Drug Carrier Systems\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020033839\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2020033839","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Exploring Therapeutic Advancement and Strategies Associated with Drug Delivery in Brain-Tumor Targeting.
Brain tumors pose a serious burden to health care because the cancers are usually incurable, despite advancements in treatment strategies including surgery, radiotherapy, and chemotherapy. Most studies report that specific drugs are effective in vitro, but many lose their therapeutic value in clinical settings. Maintaining therapeutic drug concentrations as an agent reaches a cancer target is the efficacy prerequisite for any form of treatment. However, in the case of brain tumors, the blood-brain barrier (BBB) acts to physically and physiologically block the drug, which complicates treatment options. In addition, strategies are limited by a number of factors such as difficulties that are associated with targeting tumor cells. The therapeutic potential of targeted drug delivery as an alternative to current strategies is gaining significant ground, with many studies highlighting its efficacy and compatibility in overcoming the BBB before reaching its final target in brain. In this review, we briefly describe basic physiology associated with the BBB and how modern science is taking advantage of physiological processes to deliver anticancer agents to brain. We also summarize different modes of drug delivery and highlight how nanoparticles as drug-delivery vehicles are used for drug transport in brain tumors as well as different types of surface modification that are used to increase target potential.
期刊介绍:
Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields.
Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.